Telix Completes Enrollment in Japan Phase 3 Study for Prostate Cancer Imaging Agent
Event summary
- Telix has completed enrollment of 105 patients in its Phase 3 study for TLX591-Px (Illuccix®) in Japan.
- The study aims to support a New Drug Application (NDA) for Illuccix® in Japan's nuclear medicine market.
- Telix is also seeking Conditional Approval from the PMDA to expedite the NDA review process.
- Prostate cancer is the most common cancer in Japanese men, with over 104,000 new diagnoses annually.
The big picture
Telix's completion of patient enrollment in its Phase 3 study for Illuccix® marks a significant step towards registering its prostate cancer imaging agent in Japan. This move is strategically important as prostate cancer incidence continues to rise in the Asia Pacific region, driven by aging populations and lifestyle changes. The study complements Telix's broader efforts in the Japanese market, including early access programs and other clinical trials for advanced prostate cancer treatments.
What we're watching
- Regulatory Approval
- Whether the PMDA grants Conditional Approval, which would expedite the NDA review process for Illuccix® in Japan.
- Market Expansion
- The pace at which Telix can expand access to PSMA-PET imaging in Japan, one of the world's largest nuclear medicine markets.
- Pipeline Progress
- How the completion of this study impacts Telix's broader prostate cancer portfolio activities in Japan, including other clinical trials.